Chinese gene therapy startup Exegenesis Bio Inc has gathered $10 million while Lehe Food has raised $14 million in a Series B round. Meanwhile, German drugmaker Merck has set aside $14 million for a seed fund to invest in startups in China and other Asian regions.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
